New maintenance drug aims to delay relapse in rare blood disease

NCT ID NCT03618537

First seen Dec 29, 2025 · Last updated May 14, 2026 · Updated 20 times

Summary

This study tests whether the chemotherapy drug Ixazomib, given as maintenance therapy, can help control AL amyloidosis and prevent or delay the disease from coming back. The trial involves 17 adults who have already received initial treatment. Researchers are measuring how long participants live without organ progression or needing further therapy.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, 10604, United States

  • Tufts Medical Center

    Boston, Massachusetts, 02111, United States

Conditions

Explore the condition pages connected to this study.